OncoMatch/Clinical Trials/NCT06510309
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Is NCT06510309 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Venetoclax and Rituximab for lymphoma.
Treatment: Venetoclax · Rituximab — The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL). The names of the study drugs involved in this study are: * Venetoclax (a type of inhibitor) * Rituximab (a type of antibody)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Excluded: Stage I, II
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy (rituximab)
Patients who had prior systemic therapy including rituximab
Cannot have received: radiation therapy
Exception: Palliative radiotherapy (RT) is allowed, but must be completed at least 1 week prior to treatment on this study, and prior to any baseline imaging studies or biopsies. Prior RT for gastric MALT is allowed, but must be completed at least 1 week prior to treatment on this study, and prior to any baseline imaging studies or biopsies.
Patients who have had prior radiation therapy, with the following exceptions: Palliative radiotherapy (RT) is allowed, but must be completed at least 1 week prior to treatment on this study, and prior to any baseline imaging studies or biopsies. Prior RT for gastric MALT is allowed, but must be completed at least 1 week prior to treatment on this study, and prior to any baseline imaging studies or biopsies.
Cannot have received: BTK inhibitor (ibrutinib)
Prior treatment with ibrutinib or other BTK inhibitor
Lab requirements
Blood counts
Hemoglobin ≥8.0 g/dL; absolute neutrophil count ≥1,000 cells/mcL (if bone marrow involvement, ANC ≥1500 cells/mcL); platelets ≥50,000 cells/mm3
Kidney function
Creatinine within institutional ULN OR creatinine clearance >60mL/min for patients with creatinine levels above institutional normal (by Cockcroft-Gault estimate or 12-24h creatinine clearance measurements)
Liver function
total bilirubin < 1.5 x institutional ULN (Gilberts disease or documented liver involvement: < 3 x ULN allowed); AST(SGOT)/ALT(SGPT) < 3 × institutional ULN unless elevation is caused by liver involvement with MZL
Participants must meet the following organ and marrow function as defined below: * Hemoglobin ≥8.0 g/dL * absolute neutrophil count ≥1,000 cells/mcL (In the event of documented bone marrow involvement, ANC must be ≥1500 cells/mcL) * platelets ≥50,000 cells/mm3 * total bilirubin < 1.5 x institutional upper limit of normal (ULN) (In patients with Gilberts disease or documented liver involvement, total bilirubin < 3 X ULN will be allowed) * AST(SGOT)/ALT(SGPT) < 3 × institutional ULN unless elevation is caused by liver involvement with MZL * Creatinine within institutional ULN OR creatinine clearance >60mL/min for patients with creatinine levels above institutional normal (by Cockcroft-Gault estimate or 12-24h creatinine clearance measurements)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify